Scope and coverage
- The lack of accuracy and reproducibility of radiography as the method of
end-point assessment has created difficulties for clinical trials.
- Research into biomarkers offers a possible solution to both end-point
assessment and earlier diagnosis.
- Doxycycline, Amgen's Kineret and a MMP Inhibitor from P&G offer the
most promising DMOAD prospects in the pipeline.
- Success in this area will depend heavily of clinical trial design, dosing
regimes and formulation properties of the drug.
Key findings and highlights
- Research is predominantly at an early discovery or pre-clinical stage,
with only three products in human trials. P&Gs MMP inhibitor, although
at an early stage, has shown promising results in a well-designed trial.
Tissue engineering also has great potential as a disease modifying approach,
Biosyntech currently have a product, BST-Cargel, in PI.
- The main issues dominating DMOAD research are, elucidation of the precise
mechanism and pathways involved in OA, and selection of the most effective
drug delivery approach. Delivery of the drug to the affected joint in a
sufficient concentration, without adversely affecting the rest of the body,
is proving problematic.
- The gold standard radiographic method of measuring trial outcome can lack
clinical relevance and rarely produces consistently accurate measurements.
Symptomatic outcome measurements are subjective and can be influenced by
treatments that do not alter the cartilage such as commonly used analgesics
and NSAIDs.
Reasons to purchase
- Understand the current research
- Compare DMOADs in the pipeline
- Identify the drivers and constraints in DMOAD research
|
Related Report
|
View Cart
